Streetbeat News

Stock Prices

CCL

NCLH

RCL

Shares of cruise stocks are trading higher after Carnival reported better-than-expected Q2 earnings.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:45 pm

AZN

AstraZeneca's cancer drug Imfinzi failed to meet the primary endpoint in a Phase 3 trial for early-stage lung cancer but succeeded in a Phase 3 bladder cancer study. The drug showed no new safety concerns and is being investigated in other lung cancer settings. Japan also approved AstraZeneca's Tagrisso for a specific type of lung cancer.

Portfolio Pulse from Vandana Singh

June 25, 2024 | 1:45 pm

GRAL

GRAIL shares have resumed trading after a temporary halt. This development is significant for investors as it may impact the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:40 pm

RGS

Regis Corporation shares have resumed trading and surged by 204%.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:39 pm

WVE

Wave Life Sciences Ltd (NASDAQ:WVE) announced positive results from its Phase 1b/2a SELECT-HD trial of WVE-003 for Huntington’s disease. The trial showed significant lowering of mutant huntingtin protein and preservation of healthy huntingtin protein, with no serious adverse events reported. Despite the positive results, WVE shares traded down 3.07% to $5.05.

Portfolio Pulse from Vandana Singh

June 25, 2024 | 1:37 pm

IXN

MSFT

TEAM

XLK

ZM

The European Union has charged Microsoft with anti-competitive practices for bundling its Teams app with its Office suite, potentially disadvantaging competitors like Slack and Zoom. Microsoft is attempting to address these concerns by proposing to unbundle Teams from Office products outside Europe. The company faces a potential fine of up to 10% of its annual global revenues if found guilty. Microsoft is also under scrutiny for its $13 billion partnership with OpenAI. Over the last decade, Microsoft has paid $1.71 billion in EU antitrust fines. Microsoft stock has gained over 36% in the last 12 months.

Portfolio Pulse from Anusuya Lahiri

June 25, 2024 | 1:36 pm

GRAL

ILMN

Cancer test maker Grail has started trading at $18.35 per share after being spun off from Illumina.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:33 pm

FBLG

FibroBiologics has announced preliminary proof-of-concept results for its novel artificial thymus organoid technology, which could have significant implications for regenerative medicine and immune system therapies.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:32 pm

OGEN

Oragenics Inc (NASDAQ:OGEN) shares fell by 21% to $1.03 after the company announced a proposed public offering of 1.1 million shares at $1.00 per share, expected to close around June 26. The offering aims to generate approximately $1.1 million to support the development of their ONP-002 product and general corporate purposes.

Portfolio Pulse from Henry Khederian

June 25, 2024 | 1:26 pm

NVDA

RXRX

Recursion Pharmaceuticals (NASDAQ: RXRX) shares are trading higher after CEO Chris Gibson's CNBC interview and upcoming presentation with Nvidia's Jensen Huang. The discussion focused on AI's role in drug discovery, highlighting Recursion's BioHive-2 supercomputer built with Nvidia's help. Needham analyst Gil Blum reiterated a Buy rating for RXRX with a $17 price target.

Portfolio Pulse from Adam Eckert

June 25, 2024 | 1:23 pm